NL-OMON52157尚未招募不适用
Genetic Clopidogrel response testing to finetune the antithrombotic regimen in (D)OAC Treated patients undergoing PCI - COATS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients >= 18 years of age
- •Patients indicated for indefinite (D)OAC
- •Patients undergoing successful PCI for stable or unstable (ACS) coronary
- •artery disease
- •Patients with written informed consent as approved by the ethics committee
排除标准
- •Contraindication to aspirin • Contraindication to ticagrelor or clopidogrel •
- •Under the age of 18 years • Planned cardiac surgery • Life expectancy < 1
- •year • Unable or unwilling to provide informed consent • Pregnancy • Suboptimal
- •result of stenting as defined by the operator • Need for continued triple
- •antithrombotic therapy per treating physician • Any other condition putting
- •patient at excessive risk for bleeding with ticagrelor • Use of gp2b3a
- •inhibitor • Treatment with a strong CYP3A4 inhibitor or inducer • History of
- •definite stent thrombosis
研究者
相似试验
已完成
2 期
Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56Percutaneous Coronary InterventionMyocardial InfarctionNCT01235351The TIMI Study Group335
招募中
2 期
POPular GUILTY PILOT: Genotype-guided Clopidogrel MonotherapyCYP2C19 PolymorphismAcute Coronary SyndromeNCT05926271St. Antonius Hospital200
尚未招募
4 期
Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) PatientsCoronary Arterial Disease (CAD)ACS (Acute Coronary Syndrome)SCADNCT06759272Nur Hafizah Annezah binti Utuh120
已完成
不适用
Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary SyndromeAcute Coronary SyndromeNCT01390974Assistance Publique - Hôpitaux de Paris270
终止
不适用
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes StudyCardiovascular DiseaseNCT00995514Medco Health Solutions, Inc.4,471